Eisai revises indicated uses for Neuzym medication.
+ Technology/Innovation
Jamie Barrand | Dec 12, 2015

Eisai revises indicated uses for Neuzym medication

Patients who have been using the Eisai Co. Ltd. therapy Neuzym to treat chronic sinusitis will have to find an alternative medication.

Eisai officials recently announced that the drug would undergo a partial label change to remove chronic sinusitis from the list of approved indications. A re-evaluation of the drug began in 2012, when double-blind, placebo-controlled studies showed Neuzym's effectiveness for the treatment of chronic sinusitis could not be verified.

It is still indicated for use to treat bronchitis, bronchial asthma and bronchiectasis; however, testing is ongoing, and additional label changes may occur.

Eisai is based in Tokyo, Japan. Neuzym's uses were approved by the Japanese Ministry of Health. There are six Neuzym products on the market: Neuzym Tablets, Neuzym Granules, Neuzym Fine Granules and Neuzym Syrup. All are manufactured by Sannova, Eisai's pharmaceutical subsidiary.

Organizations in this story

+ Eisai

More News